Clene Inc Ordinary Shares CLNN 深 沪
等待开盘 11-07 09:30:00 美东时间
9.25
-1.530
-14.19%
华盛通- 最 高11.2334
- 今 开10.89
- 成交量 13.25万股
- 最 低 9.22
- 昨 收 10.78
- 总市值 9314.75万
- 52周最高 13.50
- 市盈率 静 --
- 换手率 1.32%
- 52周最低 2.2801
- 委 比 70.17%
- 总股本 1007.00万
- 历史最高 356.40
- 量 比 0.54
- 振 幅 18.68%
- 历史最低 2.2801
- 每 手 1
- 风险率 1.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多澳媒：牛油果收成将创纪录，澳大利亚果农希望进入中国市场
【文/观察者网 陈思佳】澳大利亚西南部地区种植的牛油果今年有望迎来创纪录的丰收，为进一步扩大出口，澳大利亚果农将目光投向中国。据澳大利亚广播公司（ABC）11月...
11-04 20:43
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Cabaletta Bio (NASDAQ:CABA) shares rose 36.6% to $3.38 during Friday's...
11-01 01:06
Booz Allen因政府资金停滞下调业绩预期 午盘下跌10%
专题：聚焦2025年第三季度美股财报 在截至 9 月 30 日的三个月里，Booz Allen公布净利润为 1.75 亿...
10-25 00:02
第一资本金融利润大幅增长 宣布160亿美元股票回购计划
第一资本金融公司（Capital One Financial Corp．）公布第三季度利润大幅增长，超出华尔街预期。此外，这家贷款机构宣布，在收购发现金融服务公...
10-22 17:14
Clene to Participate in a Panel Discussion at the Maxim Growth Summit
<p><p>SALT LAKE CITY, Oct. 15, 2025 (GLOBE NEWSWIRE) – Clene Inc. (Nasdaq: CLNN) and its subsidiary Clene Nanomedicine Inc. announced today that management will participate in a panel discussion at the Maxim Growth Summit in New York City on October 22, 2025, and host 1x1 investor meetings. The company focuses on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases such as ALS and multiple sclerosis....
10-15 12:30
美股大行评级 | 星展银行上调百度评级至"买入"，目标价177美元；多家机构上调Guardant Health(GH)目标价最高至80美元
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12美元升至12.5美元；Oppenheimer：维持Immuneering"跑赢大市"评级，目标价从21美元升至30美元
09-26 09:45
Clene Unveils Promising Clinical Data at ECTRIMS 2025
An announcement from Clene ( ($CLNN) ) is now available. On September 25, 2025,...
09-25 20:29
D. Boral Capital Maintains Buy on Clene, Maintains $23 Price Target
D. Boral Capital analyst Jason Kolbert maintains Clene (NASDAQ: CLNN) with a Buy and maintains $23 price target.
09-25 20:16
Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients
Clene Inc. presented late-breaking clinical data at the 41st ECTRIMS Congress, showing that CNM-Au8 improved brain energy metabolism in MS and Parkinson’s disease patients by increasing the NAD+/NADH ratio. FDA expressed openness to considering cognition as a primary endpoint for broader treatment effects. Results demonstrate bioenergetic failure’s role in neurodegeneration and suggest CNM-Au8 may slow disability progression. Treatment was safe a...
09-25 12:00
